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Synovial Sarcoma is a soft tissue malignancy harboring a pathognomonic chromosomal translocation 
t(X;18)(p11.2;q11.2) producing a chimeric translocation protein called SYT-SSX. It is an aggressive 
tumor type mainly occurring in children and young adults, with a poor prognosis and no specific 
therapy. A better understanding of the molecular pathogenesis is needed to develop new therapeutic 
tools.  
 
In recent publications, it has been proven that this translocation protein deeply affects the epigenetic 
pathways of thecell. To better understand these modifications, a ChIP-Seq analysis can be performed, 
creating the need for a strong antibody target within the sequence of this chimeric protein.  
 
In this work, we induced a double strand break using a CRISPR-Cas9 system and designed a Donor DNA 
sequence with the aim to use the homology-directed repair mechanism to insert a V5 genomic tag in 
the HS-SYII cell genome. We then started preliminary work to enable precise co-infection with both 
the specific CRISPR-Cas9 system and our Donor DNA to induce the V5 tag expression in SYT-SSX.  
 
 
Keywords: Synovial Sarcoma, genome editing, SYT-SSX, cell culture, HS-SYII  
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1 Introduction  
1.1 Synovial sarcoma  
 
 
Sarcomas are a rare group of malignancies that derive from mesenchymal tissue and comprise a wide 
range of tumor types. The primary tumors can appear in a variety of different locations including bone 
and soft tissues such as fat and muscle. They can be subdivided into two groups based on the genetic 
events that are believed to drive their pathogenesis: tumors associated with unique, “signature” 
chromosomal translocations and multiple events, including point mutations, and chromosomal 
translocations, inversions and deletions without any specific pattern (1).  
 
Synovial sarcoma (SS), which represents 5 to 10% of all soft tissue sarcomas (2), is characterized by a 
specific translocation. It can occur at any age but is most commonly seen within the 15-35-year-old 
range. Contrary to what its name suggests, this type of tumor is unrelated to synovium and less than 
5% arise in a joint or a bursa. Whereas any site of the body can be affected (3), 80% of SS arise into the 
deep soft tissue, particularly around the knee next to the joint and tendons. Typical primary SS  appear 
as an infiltrative mass of 3-10cm in diameter or circumcised if slowly growing (3). There is no known 
predisposing factor leading to SS formation.  
 
It is believed that the basis of SS development resides in its pathognomonic translocation between 
chromosomes 18 and X t(X;18)(p11.2;q11.2) that results in the fusion gene called SYT-SSX. Depending 
on the SSX gene to which SS18 is fused, the fusion gene can be translated into three fusion proteins, 
namely SYT-SSX1, SYT-SSX2 or rarely SYT-SSX4.  
 
Histological analysis of SS tumors shows features that are clearly different from synovial tissues. The 
tumors typically consist of spindle cells which are small uniform ovoid cells with sparse cytoplasm and 
pale nuclei and nucleoli and/or epithelioid cells with abundant cytoplasm often arranged in glandular 
structures. Each tumor can be either monophasic, biphasic or poorly differentiated, with the majority 
– more than two thirds – displaying a monophasic phenotype (4). SS may be difficult to diagnose with 
standard immunohistochemical techniques. Therefore, molecular diagnostic tests are crucial. The 
biphasic tumors mainly harbor a SYT-SSX1 translocation and the vast majority of SYT-SSX2 tumors are 
monophasic (4).  
  
Treatment of SS barely changed in the last decades and relies on surgery for localized disease 
combined in some cases with (neo)adjuvant chemotherapy, radiotherapy or both (5). However, given 
the rarity of SS, it is difficult to conduct large prospective trials and to determine which is the best 
strategy for SS patients. In advanced disease cases, cytotoxic chemotherapies (anthracyclines) remain 
the font-line treatment, while a tyrosine kinase inhibitor (pazopanib) has also been approved as a SS 
treatment drug (6). While these treatments are showing promising results, none of them are SS-
specific.  
 
1.2 SS molecular pathogenesis.  
 
The SS fusion gene SYT-SSX encodes an oncogenic protein that drives the tumorigenesis. SS18 (SYT) is 
a ubiquitously expressed protein harboring SNH-domain and is an integral part of the chromatin 
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remodeling complex SWI/SNF, within which it interacts with the BRG1 subunit. BRG1 was also found 
to bind the  IGF2 promoter, thereby modulating IGF2 expression, which appears to be required for 
tumor formation (7)(8). SS18 also harbors a C-terminal transactivating sequence rich in glutamine, 
proline, glycine and tyrosine (QPGY domain) containing transcriptional activator sequences (9).  
 
 
Fig. 1: Molecular genetics of SS. A: Fusion gene formation, showing breakpoints on SYT and SSX as well as recombination. B: 
fusion protein, its interaction with DNA, proteins and its effect on chromatin remodeling. Image adapted from (1)    
SSX contains a repression domain (SSXRD) which contributes to transcriptional repression and a 
Kruppel-Associated box (KRAB), which is not retained in the translocation. When fused, the SYT-SSX 
gene encodes a fusion protein whose component parts have both transcriptional activation and 
repression activity.  
 
In recent years, the molecular pathogenesis of sarcomas has been an active field of study, and several 
associations with known tumorigenic mediators have been identified, opening possibilities for 
potential new therapies. For example, it has been shown that the majority of SS tumors are high Bcl-2 
expression neoplasms (10), without showing this protein to be a direct target of SYT-SSX. However, 
lower Bcl-2 levels in cell lines without the SYT-SSX fusion protein point to a possible association (11).  
SYT-SSX also has been shown to have a role in maintaining stem-cell properties and poor 
differentiation through partial Wnt-pathway activation in the absence of Wnt ligands (12). On an 
epigenetic level SYT-SSX is suggested to be a cellular context-dependent modifier, requiring a 
permissive cell state for expression and function. It participates in altering chromatin conformation to 
render its recognition sites accessible to resident transcription factors and induce gene expression. 
Many of the induced genes are developmentally regulated and participate in driving malignancy (13).  
 
Because SYT-SSX does not have a DNA-binding domain, its interaction with DNA requires association 
with other proteins. Several of these have been established, particularly within the SWI/SNF complex, 
but additional possible interactions remain to be explored as does the mechanism of chromatin 
remodeling.    
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1.3 Genome engineering techniques 
 
Genome editing techniques include an array of tools that can be used to manipulate virtually any gene 
in the genome. These techniques are based on endonucleases whose activation induces a double 
strand break (DSB) in the DNA, thereby activating the endogenous DNA repair mechanisms. These 
proteins are coupled to sequence-specific guides targeting specific DNA sites, thereby ensuring a 
precise DSB at a desired location of the genome. There are three mainly used genome editing 
techniques: zinc-fingers, TALENs and the CRISPR-Cas9 system.  
 
An individual Zinc-finger is composed of around 30 amino-acids in a beta-beta-alpha configuration with 
several amino acids on the outer alpha-helix recognizing a DNA triplet in the genome. Specific DNA-
targeting guides can then be developed by assembling a chain of zinc-finger proteins. The guide is 
coupled to a FokI endonuclease. By composing complement zinc-fingers targeting the other DNA 
strand also coupled to a FokI endonuclease, a DSB can be then induced (Fig. 2A)(14).  
 
Transcription activator-like effector nucleases (TALENs) also induce a DSB by FokI endonuclease action. 
In this system, the DNA-sequence targeting guide is composed of proteins whose amino-acid repeats 
each recognize a single base pair. These transcription activator-like effectors (TALEs) are, as zinc-
fingers, arranged in series and can recognize a specific DNA sequence (Fig. 2B)(14).  
 
The clustered regularly interspaced short palindromic repeats (CRISPR) constitutes together with the 
Cas enzyme a microbial adaptive system whose function is to cleave foreign genetic elements and has 
been derived to enable precise cuts in the genomic DNA of mammalian cells. In this system, the DSB is 
achieved by Cas9 nuclease, guided by a CRISPR-associated RNA (crRNA). An additional auxiliary trans-
activating RNA (tracrRNA) is necessary to recruit the nuclease to the target site. In experimental uses 
of this system, these two RNAs can be fused to form a single-guide RNA (sgRNA) consisting of a 20-
nucleotide sequence complementary to the target DNA sequence. One requirement for the CRISPR-
Cas9 system to work is the presence of a protospacer adjacent motif (PAM) sequence in the DNA 
directly after the target sequence, allowing for Cas9 recruitment and a DSB event. This PAM sequence 
consists of a 5’-NGG sequence (N for any nucleotide) and is present every 8-12 base pairs  in the human 
genome(Fig. 2C) (15).  
 
Fig. 2 : Genome editing techniques. A: zinc finger B: TALEN C: CRISPR-Cas9. Image adapted from 
https://www.addgene.org/genome-engineering/ 
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Compared to the other editing techniques, CRISPRs offers a few advantages. First, the sequence coding 
for the sgRNA can be easily cloned and manipulated in a short time compared to TALENs (16). Then, 
Cas9 has a specific cut site between the 17th and 18th base pairs in the target sequence (17). In 
comparison, TALENs have a non-specific cut site between their monomer-pair (18). By its ease of 
targeting, co-delivery of different sgRNAs can also be performed simultaneously, allowing 
manipulation of multiple targeted sites in the cell genome(16).  
 
1.4 DNA repair mechanisms 
 
When a DSB event occurs, two repair pathways are induced: non-homologous end joining (NHEJ) and 
homology-directed repair (HDR)(16).  
 
The NHEJ is the main repair mechanism in a mammalian cell after a DSB. It consists of the juxtaposition 
of the blunt ends and a DNA ligation. This process often results in the loss of one or more base pairs 
(19), which can be used for gene knockouts by transcription frame shifts resulting in an aberrant 
protein.  
 
HDR is based on the presence of a normal copy in the other allele. It uses this undamaged sequence 
as a template to repair the broken region, recognizing the intact allele using homology arms on each 
side of the broken area. This mechanism can be used to introduce a sequence of choice in the DNA if 
flanked by homology arms. 
 
To increase the  insertion efficiency of a new element (payload) into the genomic DNA, a few strategies 
can be used:  
- The Donor DNA containing the payload can be delivered as a single stranded DNA sequence. 
A recombinant adeno-associated virus (rAAV) can be employed for this purpose (20). This 
method is shown to increase HDR frequency by three magnitudes (21). 
- Creating a DSB by using a CRISPR-Cas9 system, which is more precise and easier to manipulate 
compared to Zinc Fingers and TALENs. 
- NHEJ can be inhibited by a drug, Scr7, increasing the HDR frequency up to 19 times (22).  
- Providing Donor DNA homology arms of different sizes would create an asymmetric Donor 
DNA that increases the insertion efficiency (23). 
 
1.5 Aim of the project 
  
To enable the discovery of specific treatments for SS, the underlying molecular mechanisms of SS need 
to be better defined and interactions between SYT-SSX fusion protein and DNA should be explored. 
Chromatin immunoprecipitation and sequencing analysis (ChIP-Seq) is one of the most frequently used 
techniques to investigate protein-DNA interactions. 
 
To conduct a successful ChIP-Seq assay, there is a need for a highly specific antibody that is able to 
immunoprecipitate the protein of interest efficiently while keeping a low count of off-target proteins. 
To date, there are no available antibodies uniquely recognizing th SYT-SSX fusion protein without cross-
reacting with the wild type SYT and/or SSX protein. To overcome this problem, in this study we aim to 
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modify genome of an established SS cell line (HS-SYII) to introduce an artificial V5 epitope tag in the 
fusion protein, which can be subsequently recognized by a V5 specific antibody.  
 
Tagging of genomic SYT-SSX is a gene knock-in that relies on HDR to drive targeted gene replacement. 
Insertion of V5 tag sequence to the intended locus will be triggered by the CRISPR-Cas9 system that 
creates a double strand break near the desired genome editing point. The HDR donor sequence will be 
introduced into cells through a rAAV transduction. It will contain two homologous regions that flank 
the V5-tag, the 2A sequence and a positive selection marker, neomycin (Neo). After HDR occurs, the 
bulk population of recombinant cells harboring V5- tagged SYT-SSX can be selected by neomycin 
treatment. The expression and localization of SYT-SSX-V5 can be confirmed by polymerase chain 
reaction (PCR), western blot and immunofluorescence. Upon confirmation of SYT-SSX- V5 harboring 
cells, ChIP-Seq studies will be started.  
2 Results  
2.1 Finding the exact breakpoint region of SYT-SSX translocation in the HSSYII 
genome 
 
While genomic sequences coding for SYT and SSX are well known and available on NCBI gene database 
(24), the exact break point location of the chromosomal translocation in between SYT on chromosome 
18 and SSX on chromosome X, t(X;18)(p11;q11) has not been established for each cell line yet.  
 
To investigate the breakpoint region of the SYT-SSX translocation in the HSSYII cell line, we performed 
genome sequencing covering the possible breakpoint regions on the HSSYII genome. The translocation 
process results in a loss of an unknown length of genomic sequence, which needed to be exactly 
defined. The initial steps to get the exact sequence was the extraction of genomic DNA and subsequent 
amplification of the possible breakpoint region by PCR covering the SYT-SSX transition, using Forward 














 Primer Name Primer sequence 
1 Forward cloning primer (FCP) 5’-TGGATATGACCAGGTAAGTAGTTTG-3’ 
2 Reverse cloning primer (RCP) 3’-GTGTAATATTTCTAGTACGGG-5’ 
3 Forward sequencing primer (FSP) 5’-CCTCAACTAGAAACTCCAATAC-3’ 
4 Reverse sequencing primer (RSP) 3’-AACCCAACTCCCAGATCC-5’ 
5 Homology arms forward primer (HAF) 5’-CCCTTTGAAATCCCTCCACTTG-3’ 
6 Homology arms reverse primer (HAR) 3’-CCCGTCTTGTTCCCTGATGTC-5’ 
7 Right homology arm forward primer (RHAF) 5’-ATCTTGTCATTTGTTTCCCAAATC-3’ 
8 Right homology arm reverse primer (RHAR) 3’-CACTCAGAACTGCCCTCAGTAG-5’ 
9 Left homology arm forward primer (LHAF) 5’-ACTTGCTGCAGCTTCTCCATCA-3’ 
10 Left homology arm reverse primer (LHAR) 3’-CATGGGCCTTCTTTATCCAG-5’ 
Table 1 : Primer list 
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Since the breakpoint mapping of SYT-SSX has not been performed for the HSSYII cell line, the exact 
length of the PCR product using FCP and RCP primers could not be determined ahead. Thus, we tried 
different extension times for the amplification of the PCR product, namely 1,2 and 3 minutes. The PCR 
products resulting from different elongation times were run on an agarose gel (0.7%). We could only 
get a PCR product with the elongation time of 3 minutes, which was around 5 to 7 kb long (Fig.3). Most 
probably, the elongation times of 1 and 2 minutes were insufficient to create a PCR product about 5-7 
kb in length for the DNA polymerase which is able to synthetize 2kb of DNA in a minute originally. 
Therefore, it needs more than two minutes to polymerize a product longer than 4kb.  
 
 
Fig. 3 : Gel run of PCR products (1), (2), (3) produced by PCR elongation times of 1, 2 and 3 minutes respectively. lambda DNA-
BstEII digest ladder (New England Biolabs) (L) was run as a reference.  
The corresponding product with 3 minutes of elongation time contained the breakpoint region. Hence, 
it was gel extracted and inserted into a TOPO vector by blunt end ligation. This plasmid named TOPO-
H1 was subsequently sequenced. Finding the exact breakpoint region of the translocation was 
achieved by sequencing the PCR product inserted into Topo vector. The breakpoint was found using 
Forward sequencing primer (FSP) and Reverse sequencing primer (RSP); namely: primers 3 & 4 (Table 
1).  
 
Comparing to the full-length genomic sequences of SYT and SSX genes, we found that a 8625 bp-long 
region was lost during the SYT-SSX translocation in the HS-SYII genome. 
 
Fig. 4 : Translocation breakpoint. A: Forward cloning primer (FCP) initiates 5' to 3' transcription from SYT last exon (LE) while 
reverse cloning primers (RCP) initiates 3’ to 5’ transcription from SSX first exon. PCR amplification covers the breakpoint (BP). 
B: Exact sequence of breakpoint (BP) region, sequenced using forward sequencing primer (FSP) and reverse sequencing primer 
(RSP), which showed an overlap in the sequences they allowed to acquire.  
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2.2 Design and cloning of the CRISPRs targeting the region of interest 
 
In this study we wanted to modify genome of HSSYII to introduce an artificial V5 epitope tag in the 
fusion protein, which can be subsequently recognized by a V5 specific antibody.  
 
This gene knock-in uses the HDR pathway to drive targeted gene replacement. Insertion of V5 tag 
sequence to the intended locus was triggered by a DSB induced by a CRISPR-Cas9 system. 
 
A CRISPR-Cas9 complex is composed of two components. A 20 nucleotide RNA (guide RNA) which is 
the reverse complement to the targeting region on DNA, and Cas9 protein that induces a double strand 
break near the desired genome editing point, which in turn activates the DNA repair mechanisms.  
 
The target region on the genome, reverse complement to the guide RNA, needs to be directly adjacent 
to a PAM sequence. We searched a target region in the vicinity of the last SYT exon and its stop codon 
using online tools: namely crispr.mit.edu and chopchop.cbu.uib.no. Two guide RNA sequences with 
the highest scores were chosen to continue with cloning experiments.  
 
 
Fig. 5: Crispr system. A : sgRNA 1&2 in a pLentiCRISPRv2 vector containing Ampicillin resistance gene (AmpR), puromycin 
resistance gene (PuroR) and Streptococcus-derived Cas9 nuclease. U6 promoter & EF1-alpha promoter regulate gene 
expression in this plasmid. BsmBI restriction sites allow for sgRNA insertion. B: CRISPR 1 & 2 target sites around the last SYT-
SSX exon. 
 
The oligonucleotides coding for the top two guide RNAs were inserted into a plasmid producing Cas9 
protein (#52961, Addgene). In this vector, the expression of Cas9 is under the control of EF1-alpha 
promoter and the transcription of the sgRNA is regulated by U6 promoter (Fig 5A). Furthermore, the 
backbone carries antibiotic resistance genes, for instance; ampicillin is to select transfected bacteria 
and puromycin is to select infected HSSYII cells.  
 
2.3 Detailed design of the donor DNA  
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We design a HDR donor sequence (donor DNA) which can be introduced to cells through a rAAV. Donor 
DNA contains 3 elements: a left homology arm (LHA), a right homology arm (RHA) and the payload. 
The payload consists of the V5-tag sequence, 2A sequence, two LoxP sites and the Neomycine 
resistance gene. Besides, LHA and RHA of different sizes flank the payload asymmetrically (Fig 6 & 7).  
  
We used a traditional cloning based on restriction sites and ligation to generate our rAAV plasmid 
carrying homology arms and payload sequence, all of which creates donor DNA (Fig 6).  
 
 
Fig. 6: Assembly of donor plasmid. Left homology arm (LHA) is digested by AccI and EcoRI restriction enzymes. Donor DNA 
(payload) is digested with EcoRI and AvrII restriction enzyme. Right homology arm (RHA) is digested with AvrII and BglII 
restriction enzymes. These three parts were extracted from a TOPOblunt backbone. The Adeno-Associated Virus backbone 
(pAAV) is digested with AccI and BglII restriction enzymes. The four parts are then assembled by four-way ligation to construct 
the definitive plasmid carrying the donor DNA. Schemes are not in scale.  
 
2.3.1 Homology arms 
 
The genomic DNA sequence containing both of the homology arms were amplified from the previously 
established TOPO-H1 plasmid using primers 5&6 (Table 1). The subsequent PCR product was gel 
extracted and cloned into a TOPO vector. Then, we created RHA and LHA using pairs of primers 7-8 
and 9-10, respectively. The PCR products were gel extracted and inserted into a TOPOblunt vector 
individually to create LHA-TOPOblunt and RHA-TOPOblunt plasmids (Fig 6).  
 
 
2.3.2 Payload  
 
The payload DNA is the sequence carrying the V5 tag, which is in frame with the stop codon. It is also 
designed to provide tools to detect random insertions and to allow for later knockout experiments.  
 
By designing a promoterless system, we insured that the antibiotic selection process would select only 
the cells in which the payload is inserted in the target location. This way, the Neo resistance is acquired 
only if the donor sequence is inserted into the target location, which is under the control of SSX exon 
promoter. In this design the Neo region is preceded by a 2A sequence allowing for the independent 




Fig. 7: HDR scheme. Upper panel: double strand break in the SYT-SSX fusion chromosome, around the stop codon (in red). 
Lower panel: Donor DNA with Emerald Green Fluorescent Protein (EmGFP), left (LHA) and right (RH) homology arms flanking 
the payload (GBlock). The payload is constructed with the sequences of the last exon (LE), the V5 tag, the 2A sequence and 
the LoxPsites (triangles) around the Neo region and the stop codon (in red). Schemes are not in scale.  
The Emerald Green Fluorescent Protein (EmGFP) is a tool to detect random insertions which can 
happen in off-target parts of the genome. Normally, it is expected that the cells having a random 
insertion would not express EmGFP or any other coding sequences in payload since donor DNA does 
not contain any promoter. However, the cells containing a random insertion could still express EmGFP, 
if only the random insertion is in frame with an active gene being expressed which is very unlikely. 
Even it happens, cells with EmGFP expression can be detected and eliminated by cell sorting. On the 
other hand, being placed upstream of the left homology arm in 5’ direction, the EmGFP sequence 
would not be introduced in the genome in case of HDR event in the targeted DNA region. 
 
 
Fig. 8 : Payload sequence. The Payload sequence consists in the last SYT-SSX exon followed by the V5 tag sequence, the 2A 
sequence and Neo region, which is flanked by two LoxP sites facing each other.  
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Moreover, there are LoxP sites on both sides of the Neo sequence, allowing for knockout experiments 
once the payload is inserted. This knockout would be initiated by Cre enzyme inducing the sequence 
to flip over, shifting the stop codon in the non-sense mediated RNA decay window and thereby 
inducing the mRNA degradation and knocking the SYT-SSX fusion protein out. 
 
The synthetic DNA fragment containing the payload sequence was inserted into a TOPOBlunt 
backbone. Eventually, it was cloned into pAAV backbone together with LHA and RHA (Fig. 6). 
 
2.4 Viral production and infection of HSSY2 cells 
2.4.1 CRISPR lentivirus 
 
To produce the lentiviruses for infection of HSSYII cells with CRISPR vectors, we performed liposome-
based transfection of HEK293T cells using FuGENE HD transfection Reagent. We co-transfected the 
CRISPR1 & CRISPR2 plasmids together with envelope and packaging plasmids to produce lentiviruses. 
After 48h, the cells were harvested and the virus were collected (see materials and method, part 4.6), 
thereby producing a virus stock.  
 
 
Fig. 9: Lentiviral titration results. A :  Graph showing the ct values (y-axis) according to the copy numbers (x-axis, in log10 
scale). B: table with effective virus copy number, number of cells infected and multiplicity of infection for each CRISPR 
lentivirus.  
After transfection and virus harvest, we separately infected 0.4 M HS-SYII cells with CRISPR1 & 2 and 
titrated the virus using RT-qPCR. An uninfected sample (HS-SYII_WT) of the same cell number was also 
analyzed as control. From these results we then calculated the multiplicity of infection (MOI), 
corresponding to the viral copy number integrated in the genome of the infected cells. We were also 
able to calculate the viral copy concentration (copy number per ul) of our lentiviral stock harvested 
from HEK293T cells. These results can be used for later dual infection with a wanted MOI, insuring for 
the vast majority of cells to be infected with our virus.  
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2.4.2 rAAV production 
 
The adeno-associated virus was produced in a similar manner to lentiviruses. It was co-transfected on 
HEK293T cells with envelope and packaging sequences and thereby producing a stock from which we 
used different volumes to infect HS-SYII cells.  
 
 
Fig. 10: Adeno-associated virus titration results and cell viability test. A: Graph showing the ct values (y-axis) according to 
the copy number of donor sequence (x-axis, in log10 scale). B: Table showing MOI results with different volumes of virus 
stock and the MOI corresponding to each volume. C: cell viability test after infection, pictures at 10x after 6 and 10 days of 
infection.  
 
We titrated the viral infection by real-time quantitative polymerase chain reaction (RT-qPCR) (fig 10A) 
and calculated the MOI from the results (fig. 10B). The cells were then kept in culture to determine  
their viability (fig. 10C) after infection. Cells kept growing after infection showing that the infection 
with pAAV plasmid had no toxicity up to an infection with 30 µl of our virus stock.  
 
2.5 Dual infection  
 
A dual transduction with rAAV-Donor and both CRISPR vectors was performed as a preliminary 
infection with use of Scr7. The co-infected HS-SYII cells were then selected for 10 days using Neomycin. 
At the end of the selection process, only a few bulk populations of cells were found on the plate which 
are expected to have V5 tag integration in their genome (see fig. 11).  
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Fig. 11 : Bulk HS-SYII populations after a 10-days selection under Neomycin.   
3 Discussion 
 
In this project we have demonstrated the work needed to introduce a high-affinity and low cross-
reacting antibody target sequence specific to the SYT-SSX fusion protein, namely the V5 tag sequence. 
This genomic engineering requires using the HDR pathway.  
 
Because HDR events are rare, we enhanced their efficiency by delivering our payload in a rAAV vector 
and flanked by two asymmetrical homology arms and used a CRIPR-Cas9 system to induce a precise 
DSB in the required location. We inhibited NHEJ by administering Scr7 at the time of infection.  
 
The payload was designed to harbor the V5-tag sequence in frame with the last SYT-SSX exon. It also 
contains a Neomycin resistance gene to detect random insertions, which is preceded by a 2A sequence 
allowing for the transcription of an independent mRNA simultaneously as the SYT-SSX transcription. 
This Neo region is flanked by two LoxP sites for later knockout of SYT-SSX by Cre recombination.  
 
We demonstrated that the HSSYII cells are infectible with rAAV-Donor as well as CRISPR lentiviruses. 
A dual infection was performed as a preliminary experiment and the cells that survived the selection 
process remain to be tested for the harboring of the V5-tag. The V5-tag can be detected by Western-
blotting using a specific anti-V5 antibody and looking for a protein with a molecular weight compatible 
in size with SYT-SSX-V5.   
 
A precise double infection with one of the CRISPRs and the rAAV-Donor virus still has to be performed, 
with controlled volumes from the produced virus stocks aiming for a MOI of 4-5. This would insure the 
infection of approximately 99% of the cells with at least one viral particle. Again, the presence of the 
SYT-SSX fusion protein would be checked by Western-blotting. Following the positive selection with 
Neomycin, a RT-qPCR will be performed with primers specific to SYT-SSX and to V5-tag. Finally, a 
genomic sequencing of the targeted DNA region will insure for the correct sequence of the inserted 
payload.  
 
This insertion allows for a ChiP-seq analysis precipitating the SYT-SSX fusion protein. This will allow the 
analysis of DNA binding sites and chromatin state in edited cells. Recent works using a similar 
technique have shown the fusion protein to deregulate developmental programs by hijacking the 
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repressive complex KDM2B-PRC1.1 (25). This in turn is proposed to drive synovial sarcoma 
oncogenesis.  
4 Material and Methods 
 
 
4.1 Extraction of genomic DNA and amplification of possible breakpoint locus 
 
The genomic DNA was extracted from HSSYII cells using a kit (QIAgen) according to manufacturer’s 
instructions. Possible breakpoint locus on genome was amplified by PCR using Phusion polymerase 
(New England Biolabs) and an elongation time of 1, 2 and 3 minutes. The products were run on a gel 
and the PCR product of the 3 min elongation time was extracted from the gel (Qiagen). It was then 
inserted into a TOPO vector by ligation with an incubation time of 10 min at 25°C.  
 
4.2 Insertion vector 
 
The donor DNA was inserted into pAAV backbone in a two-step digestion with restriction enzymes 
Acc1 and Bgl2 with an incubation time of 1hr at 37°C. The two products were separated from each 
other by electrophoresis in an agarose gel. The product corresponding to the backbone had a total 
length of 4150bp and was then extracted.   
 
The 5’HA homology arm was amplified from the previously extracted genomic DNA (TOPO-H1) and 
inserted into TOPOBlunt vector PCR blunt ligation with an incubation time of 10min at 25°C. The result 
was then precipitated using butanol and resuspended in H2O. It was electroporated into Stbl3 and 
incubated at 37°C overnight. After PCR screening two colonies were chosen, miniprepped and sent to 
sequencing.  It was then prepared for ligation with a one-step double digestion by Acc1 and EcoR1-HF 
at 37°C for 1h and products separated using electrophoresis on an agarose gel. The corresponding 
product was identified with its length of 1010bp and extracted. 
 
The 3’HA homology arm was also amplified from the extracted genomic DNA and ligated by a PCR 
blunt ligation for 10min at 25°C, resuspended in H2O and electroporated into Stbl3 and incubated 
overnight. Three colonies from the PCR screening were miniprepped and sent to sequencing.  It was 
then prepared for ligation with a two-step double digestion by Acc1 and EcoR1-HF at 37°C for 1h and 
products separated using electrophoresis on an agarose gel. The corresponding product was identified 
with its length of 581bp and extracted.  
 
The payload insert was designed and ordered from Integrated DNA technologies. It was inserted in a 
TOPOblunt vector by blunt-end ligation with an incubation time of 10 min at 25°C. The product was 
precipitated with butanol, resuspended in H20, electroporated in Stbl3 strain of E. coli and incubated 
overnight. After PCR screening 3 colonies were chosen and sent to sequencing. The preparation for 
ligation with homology arms consisted in a one-step double digestion using first AvrII and then Bgl2, 
both with an incubation time of 1h at 37°C. The products were separated with an electrophoresis on 
an agarose gel. The expected product of 1721bp was then extracted.  
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The ligation of the four products was performed in a 4-way ligation using T4 ligase with an incubation 
time of 10min at 25°C. The product was then precipitated with butanol, resuspended in H2O and 
electroporated into GLSHOT strain of E. coli and incubated for 72h at 24°C. After a PCR screening, 3 
colonies were chosen for the subsequent miniprep plasmid extraction and sent for sequencing.  One 
of them with the correct sequence was then chosen to continue. 
 
All the gel extractions were performed using QIAquick extraction kit from Qiagen and the products 
were then resuspended in elution buffer from the kit.  
 
All sequencings were performed using Sanger sequencing method. This process was performed by 
Microsynth AG.   
 
 
4.3 CRISPR cloning 
 
The two guide RNA sequences cloned into CRISPR plasmid were designed using crispr.mit.edu and 
chopchop.cbu.uib.no online tools. They were designed with overhangs 5’-3’ CACC and 3’-5’ AAAC, 
making them compatible for subsequent sticky-end ligation with the lentiviral vector 
 
The guide RNA oligonucleotides were suspended in annealing buffer and annealed on a thermocycler 
with 70 cycles consisting of 5minutes at 95°C followed by 30seconds at -1°C, producing two 10 uM 
annealed CRISPR stocks. Before insertion into the lentiviral vector, the annealed stocks were diluted 
1/100 to a concentration of 100nM.  
 
The lentiviral vector lentiCRISPRv2 was ordered on Addgene website (26). It was suspended according 
to manufacturer specifications. It was prepared for ligation by digestion with restriction enzyme BsmbI 
with an incubation time of 1h at 37°C. The products were separated with agarose gel electrophoresis 
and the product of 12988bp, corresponding to the vector, was then extracted.  
 
The annealed guide RNA oligonucleotides and vector backbone were ligated together by sticky-end 
ligation with T4 ligase with an incubation time of 10min at 65°C. The product was precipitated with 
butanol, electroporated into GLSHOT strain of E.coli and incubated overnight. After miniprep, five 
colonies were chosen and sent to sequencing.  One colony of each CRISPR construct was chosen to 
continue.  
 
4.4 Cell culture 
 
HS-SYII cells were cultured in DMEM with 10% fetal bovine serum (FBS)(Gibco) and 1% penicillin-
streptomycin (PS)(Gibco). They were cultured in 15cm petri dishes and kept at 37°C, 5% CO2. 
 
HEK 293T cells were cultured in DMEM with 10% FBS, 1% PS and 1% non-essential amino-acids 




4.5 Virus production 
 
The viruses were produced using the Fugene HD transfection kit (Promega).  
 
Regarding both lentivirus production of CRISPR constructs, we used pMD2G as envelope plasmid and 
PCMVDelta R8.74 as packaging plasmid. They were then transferred on 4 million HEK 293T and the cell 
medium was changed after 24h.  
 
pHelper and pRC2 were used respectively, as envelope and packaging plasmids for the production of 
rAAV containing the Donor DNA. The reaction was transferred onto 12 million HEK 293T cells and the 
cell medium was changed after 12h. 
 
4.6 Virus harvesting 
 
 
The rAAV virus carrying the donor DNA was harvested using AAVpro Helper Free System (TAKARA BIO 
Inc.) reagents 48h after transfection. 
 
The CRISPR viruses were harvested using Lenti-X Concentrator (Clontech Laboratories Inc.) reagent 
48h after transfection. 
 
4.7 Infection and selection of HSSYII cells 
 
We first infected cells with only CRISPR 1 or 2 lentivirus and rAAV independently.  
 
HSSYII cells were infected with the lentiviruses carrying CRISPR backbones or rAAV containing the 
donor DNA. The mediums of the cells were changed 10h after infection. We selected the infected cells 
using Neomycin (1mg/ml) for 10 days.  
 
A dual infection was performed as a preliminary experiment with rAAV extracted particles (2.5ul of 
stock) together with the filtrated medium of CRISPR1 infected HEK293T cells. We used 2ul of Scr7, 
thereby inhibiting NHEJ. 
 
4.8 Virus titration  
 
rAAV-Donor viruses were titrated and mulptiplicity of infection was calculated by RT-qPCR using 
AAVpro Titration kit (TAKARA BIO Inc.) reagents.  
 
CRISPR 1&2 lentiviruses were titrated using a protocol developed by Barde et al. (27), and adapted for 
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